Insights into the binding mode of AS1411 aptamer to nucleolin [PDF]
Frontiers in Molecular Biosciences, 2022 AS1411 aptamer can function as a recognition probe to detect the cell surface nucleolin overexpressed in cancer cells, however, little is known about their binding process.
Lianjun Zhang, Fuze Jiang
exaly +7 more sources
Locking up the AS1411 Aptamer with a Flanking Duplex: Towards an Improved Nucleolin-Targeting [PDF]
Pharmaceuticals, 2021 We have designed AS1411-N6, a derivative of the nucleolin (NCL)-binding aptamer AS1411, by adding six nucleotides to the 5′-end that are complementary to nucleotides at the 3′-end forcing it into a stem-loop structure. We evaluated by several biophysical
Carla Cruz +2 more
exaly +7 more sources
Radiosensitization of breast cancer cells using AS1411 aptamer-conjugated gold nanoparticles [PDF]
Radiation Oncology, 2021 Background Gold nanoparticles (GNPs) have been used to sensitize cancer cells and enhance the absorbed dose delivered to such cells. Active targeting can provide specific effect and higher uptake of the GNPs in the tumor cells, while having small effect ...
Somayeh Sadat Mehrnia +4 more
doaj +6 more sources
Anti-nucleolin aptamer AS1411: an advancing therapeutic
Frontiers in Molecular Biosciences, 2023 Targeted therapy is highly desirable, as it allows for selective cytotoxicity on diseased cells without off-target side effects. Nucleolin is a remarkable target for cancer therapy given its high abundance, selective presence on the plasma membrane, and ...
Neelam Sharma-Walia
exaly +5 more sources
Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14. [PDF]
PLoS ONE, 2016 Aptamers are small synthetic oligonucleotides that bind to target proteins with high specificity and affinity. AS1411 is an aptamer that binds to nucleolin, which is overexpressed in the cytoplasm and occurs on the surface of cancer cells.
Yuri Cho +11 more
doaj +6 more sources
AS1411 Aptamer Linked to DNA Nanostructures Diverts Its Traffic Inside Cancer Cells and Improves Its Therapeutic Efficacy [PDF]
Pharmaceutics, 2021 The nucleolin-binding G-quadruplex AS1411 aptamer has been widely used for cancer therapy and diagnosis and linked to nanoparticles for its selective targeting activity.
Giulia Vindigni +6 more
doaj +2 more sources
Phosphorothioated amino-AS1411 aptamer functionalized stealth nanoliposome accelerates bio-therapeutic threshold of apigenin in neoplastic rat liver: a mechanistic approach [PDF]
Journal of Nanobiotechnology, 2023 Hepatocellular carcinoma (HCC) is a leading cause of death globally. Even though the progressive invention of some very potent therapeutics has been seen, the success is limited due to the chemotherapeutic resistance and recurrence in HCC.
Moumita Dhara +6 more
doaj +2 more sources
Anti-Proliferative Effect of Doxorubicin-Loaded AS1411 Aptamer on Colorectal Cancer Cell. [PDF]
Asian Pac J Cancer Prev, 2021 Doxorubicin (Dox) inhibits DNA replication and causes DNA damage resulting in cell death. It is a common drug for treatment of many cancers. Treatment efficacy and side effects of Dox are critical issues in using it because the drug lacks of specificity. The objective of this study was to improve the specificity of Dox by the incorporation of this drug
Lohlamoh W +2 more
europepmc +4 more sources
Nucleolin-Targeting AS1411 Aptamer-Conjugated Nanospheres for Targeted Treatment of Glioblastoma. [PDF]
PharmaceuticsPost-operative chemotherapy is still required for the treatment of glioblastoma (GBM), for which nanocarrier-based drug delivery has been identified as one of the most effective methods. However, the blood-brain barrier (BBB) and non-specific delivery to non-tumor tissues can significantly limit drug accumulation in tumor tissues and cause damage to ...
Seo K +5 more
europepmc +5 more sources
Targeted delivery of doxorubicin and therapeutic FOXM1 aptamer to tumor cells using gold nanoparticles modified with AS1411 and ATP aptamers [PDF]
Iranian Journal of Basic Medical Sciences, 2023 Objective(s): A targeted delivery platform was prepared to co-deliver both doxorubicin (Dox) as an anticancer drug and FOXM1 aptamer as a therapeutic substance to breast cancer cells (4T1 and MCF-7) to reduce Dox side effects and increase its therapeutic
Aref Abdollahzade +6 more
doaj +3 more sources